Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Our professional view is that you don't need to choose between them
$79.99 CAD, taxes and shipping shown before payment Use Notice: This item is intended for qualified laboratory purchasers only
In September 2019, the first oral GLP-1R agonist for T2D was approved by FDA (Mosenzon et al., 2019
[79] showed that adenovirus-induced OGA overexpression and OGT knockdown failed to restore impaired Akt activation by insulin stimulation and prevent glucose-induced insulin resistance in 3T3L1 adipocytes, and in another study, treatment with the OGA inhibitor 1,2-dideoxy-2-propyl---glucopyranoso-[2,1, D]-2-thiazoline (NButGT) did not induce insulin resistance characterized by defective glucose uptake and Akt phosphorylation in 3T3-L1 adipocytes [80]
Most Common Sizes: 1ml Vial (100 units): $350 2ml Vial (200 Units) - 6 Week Program: $550 Weeks 1-4: 25 Units (2.5mg) Weeks 5-6: 50 Units (5mg) 3ml Vial (300 Units) - 8 Week Program: $700 Weeks 1-4: 25 Units (2.5mg) Weeks 5-8: 50 Units (5mg) Looking for other options
Anti-Inflammatory & Antioxidant Effects GHK-Cu fights oxidative stress and chronic inflammation, which are the two major culprits behind aging and disease
US$ 24.01
US$ 23.30
US$ 29.75
